Lilly Receives Positive CHMP Opinion for Emgality(TM) (galcanezumab) for the Prophylaxis of Migraine in Adults

INDIANAPOLIS, Sept. 21, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE :LLY ) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for... Biopharmaceuticals, Neurology, Regulatory Eli Lilly, Emgality, galcanezumab, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news